DRD3 and ablepharon macrostomia syndrome: We mapped the dopamine receptor family DRD1, DRD3, and other targets for improving sleep disorders with the components of AMS to the dopaminergic metabolic signaling pathway and constructed a metabolic pathway map (Figure 5).